Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I)
The efficacy, safety, cost-effectiveness and mechanism of action of the anti-TNF antibody infliximab in patients with AP is tested and potential safety signals will be adverse events related to infliximab.